Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James Douglas Griffin, M.D.

Co-Author

This page shows the publications co-authored by James Griffin and Ellen Weisberg.
Connection Strength

21.259
  1. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543.
    View in: PubMed
    Score: 0.892
  2. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020 Aug 10; 37(9):167.
    View in: PubMed
    Score: 0.888
  3. Current therapies under investigation for COVID-19: potential COVID-19 treatments. Can J Physiol Pharmacol. 2020 Aug; 98(8):483-489.
    View in: PubMed
    Score: 0.883
  4. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980.
    View in: PubMed
    Score: 0.855
  5. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156.
    View in: PubMed
    Score: 0.854
  6. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629.
    View in: PubMed
    Score: 0.832
  7. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501.
    View in: PubMed
    Score: 0.825
  8. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. Onco Targets Ther. 2018; 11:175-182.
    View in: PubMed
    Score: 0.741
  9. Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15; 8(66):109973-109984.
    View in: PubMed
    Score: 0.734
  10. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06.
    View in: PubMed
    Score: 0.717
  11. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044.
    View in: PubMed
    Score: 0.717
  12. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther. 2015 Oct; 14(10):2249-59.
    View in: PubMed
    Score: 0.626
  13. Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. Arch Toxicol. 2014 Dec; 88(12):2233-42.
    View in: PubMed
    Score: 0.594
  14. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res. 2014 Nov 01; 20(21):5483-95.
    View in: PubMed
    Score: 0.589
  15. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 2015 Jan; 29(1):27-37.
    View in: PubMed
    Score: 0.575
  16. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011; 6(9):e25351.
    View in: PubMed
    Score: 0.481
  17. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010 Oct; 1(10):1021-32.
    View in: PubMed
    Score: 0.449
  18. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010 Dec; 24(12):2100-9.
    View in: PubMed
    Score: 0.447
  19. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther. 2010 Sep; 9(9):2468-77.
    View in: PubMed
    Score: 0.446
  20. Drug resistance in mutant FLT3-positive AML. Oncogene. 2010 Sep 16; 29(37):5120-34.
    View in: PubMed
    Score: 0.442
  21. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010 May 27; 115(21):4206-16.
    View in: PubMed
    Score: 0.432
  22. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun; 12(3):81-9.
    View in: PubMed
    Score: 0.408
  23. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15; 112(13):5161-70.
    View in: PubMed
    Score: 0.390
  24. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther. 2008 May; 7(5):1121-9.
    View in: PubMed
    Score: 0.379
  25. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood. 2008 Apr 01; 111(7):3723-34.
    View in: PubMed
    Score: 0.371
  26. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther. 2007 Jul; 6(7):1951-61.
    View in: PubMed
    Score: 0.358
  27. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007 May; 7(5):345-56.
    View in: PubMed
    Score: 0.354
  28. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 01; 109(5):2112-20.
    View in: PubMed
    Score: 0.342
  29. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology. 2006 Dec; 131(6):1734-42.
    View in: PubMed
    Score: 0.339
  30. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19; 94(12):1765-9.
    View in: PubMed
    Score: 0.332
  31. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb; 7(2):129-41.
    View in: PubMed
    Score: 0.303
  32. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia. 2004 Dec; 18(12):1951-63.
    View in: PubMed
    Score: 0.299
  33. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat. 2003 Oct; 6(5):231-8.
    View in: PubMed
    Score: 0.276
  34. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002 Jun; 1(5):433-43.
    View in: PubMed
    Score: 0.252
  35. Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia. 2022 Apr; 36(4):1048-1057.
    View in: PubMed
    Score: 0.245
  36. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat. 2001 Feb; 4(1):22-8.
    View in: PubMed
    Score: 0.230
  37. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000 Jun 01; 95(11):3498-505.
    View in: PubMed
    Score: 0.219
  38. Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184.
    View in: PubMed
    Score: 0.214
  39. Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry. 2018 02 06; 57(5):477-478.
    View in: PubMed
    Score: 0.184
  40. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
    View in: PubMed
    Score: 0.182
  41. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015 May 14; 125(20):3133-43.
    View in: PubMed
    Score: 0.153
  42. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473.
    View in: PubMed
    Score: 0.132
  43. Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. Gene. 2004 Mar 17; 328:153-65.
    View in: PubMed
    Score: 0.071
  44. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol. 2003; 532:121-40.
    View in: PubMed
    Score: 0.066
  45. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 2022 01; 36(1):210-220.
    View in: PubMed
    Score: 0.059
  46. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592.
    View in: PubMed
    Score: 0.059
  47. 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. Leuk Lymphoma. 2021 10; 62(10):2457-2465.
    View in: PubMed
    Score: 0.059
  48. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001 Apr 15; 97(8):2440-8.
    View in: PubMed
    Score: 0.058
  49. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1).
    View in: PubMed
    Score: 0.057
  50. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324.
    View in: PubMed
    Score: 0.054
  51. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chem Biol. 2018 01 18; 25(1):88-99.e6.
    View in: PubMed
    Score: 0.046
  52. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650.
    View in: PubMed
    Score: 0.045
  53. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 02 01; 25(3):838-846.
    View in: PubMed
    Score: 0.043
  54. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem. 2017 02 15; 25(4):1320-1328.
    View in: PubMed
    Score: 0.043
  55. Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. 2016 Aug 16; 7(33):53515-53525.
    View in: PubMed
    Score: 0.042
  56. Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 May 31; 7(22):32641-51.
    View in: PubMed
    Score: 0.042
  57. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17; 7(20):29131-42.
    View in: PubMed
    Score: 0.041
  58. Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett. 2016 May 12; 7(5):476-81.
    View in: PubMed
    Score: 0.041
  59. Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leuk Res. 2015 Sep 09.
    View in: PubMed
    Score: 0.039
  60. Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015 Jul; 29(7):1555-1563.
    View in: PubMed
    Score: 0.038
  61. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91.
    View in: PubMed
    Score: 0.036
  62. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013 Oct 18; 8(10):2145-50.
    View in: PubMed
    Score: 0.034
  63. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol. 2013 Jul 19; 8(7):1423-8.
    View in: PubMed
    Score: 0.034
  64. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11.
    View in: PubMed
    Score: 0.032
  65. Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. Bioorg Med Chem Lett. 2012 Aug 15; 22(16):5297-302.
    View in: PubMed
    Score: 0.032
  66. An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRa and kit. Bioorg Med Chem Lett. 2012 Jul 15; 22(14):4579-84.
    View in: PubMed
    Score: 0.032
  67. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12):3421-9.
    View in: PubMed
    Score: 0.029
  68. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
    View in: PubMed
    Score: 0.027
  69. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005 Jun; 19(8):960-2.
    View in: PubMed
    Score: 0.019
  70. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
    View in: PubMed
    Score: 0.018
  71. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk Lymphoma. 2003 Nov; 44(11):1987-96.
    View in: PubMed
    Score: 0.017
  72. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
    View in: PubMed
    Score: 0.017
  73. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69.
    View in: PubMed
    Score: 0.017
  74. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
    View in: PubMed
    Score: 0.016
  75. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15; 99(2):664-71.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.